Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 3/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.41 |
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.39 |
| ▸ | DAO | P14920 | 4/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | IKBKB | O14920 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL27510835 | 0.98 | PKM (0.47) | PKMRXFP1NPSR1KDM4EMAPT | |
| SCHEMBL23096771 | 0.83 | MAPT (0.53) | PKMRXFP1NPSR1KDM4EMAPT | |
| SCHEMBL15943484 | 0.83 | IKBKB (0.50) | PKMRXFP1KDM4EMAPTLMNA | |
| SCHEMBL10737979 | 0.79 | MAPT (0.35) | PKMRXFP1NPSR1KDM4EMAPT | |
| SCHEMBL166726 | 0.78 | MAPT (0.54) | KDM4EMAPTALDH1A1MEN1KMT2A | |
| SCHEMBL5493304 | 0.77 | IKBKB (0.40) | PKMRXFP1NPSR1KDM4EMAPT | |
| SCHEMBL5104631 | 0.77 | PKM (0.52) | PKMRXFP1NPSR1KDM4EMAPT | |
| Hydrochloric Acid SCHEMBL10735502 | 0.76 | MAPT (0.53) | KDM4EMAPTALDH1A1MEN1KMT2A | |
| SCHEMBL3229132 | 0.76 | GPR35 (0.45) | PKMRXFP1KDM4EMAPTLMNA | |
| SCHEMBL4547877 | 0.76 | ALDH1A1 (0.55) | PKMRXFP1NPSR1KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8476278-B2 | Thiazole Derivatives as protein kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-07-02 | — | — | US | disclosed |
| US-20100331313-A1 | Thiazole Derivatives as Protein Kinase Inhibitors | SCHERING CORPORATION | 2010-12-30 | — | — | US | disclosed |
| EP-0269295-B1 | THERAPEUTIC AGENTS | The Boots Company PLC (GB) | 1991-06-26 | — | — | EP | disclosed |
| US-4877793-A | CARDIOVASCULAR DISORDERS | THE BOOTS COMPANY, PLC (GB) | 1989-10-31 | — | — | US | disclosed |
| EP-0269295-A1 | Therapeutic agents | The Boots Company PLC (GB) | 1988-06-01 | — | — | EP | disclosed |
| EP-0025643-B1 | OXO-PYRIDO(1,2-A)THIENOPYRIMIDINE COMPOUNDS, PROCESSES FOR THEIR PRODUCTION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAID COMPOUNDS | WARNER-LAMBERT COMPANY (US) | 1983-08-17 | — | — | EP | disclosed |
| US-4332947-A | TREATMENT OF ALLERGIES | WARNER-LAMBERT COMPANY (US) | 1982-06-01 | — | — | US | disclosed |
| US-4287340-A | USEFUL AS ANTIALLERGENS | WARNER-LAMBERT COMPANY (US) | 1981-09-01 | — | — | US | disclosed |
| EP-0025643-A1 | Oxo-pyrido(1,2-a)thienopyrimidine compounds, processes for their production, and pharmaceutical compositions containing said compounds | WARNER-LAMBERT COMPANY (US) | 1981-03-25 | — | — | EP | disclosed |
| US-4230707-A | ANTIALLERGENS | WARNER-LAMBERT COMPANY (US) | 1980-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331313-A1 | Thiazole Derivatives as Protein Kinase Inhibitors | DAPK2, DAPK1, JAK1 | PKM 1013/4885RXFP1 4361/4885NPSR1 3445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.